Swallowing in OSA & CPAP Intolerance
Launched by DENISE DEWALD · Jan 14, 2025
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Obstructive sleep apnea (OSA) is a common disorder in which the throat narrows abnormally or even collapses fully during sleep. The narrowing leads to sleep disruption and increases the risk of many chronic health conditions. We do not understand why the throat narrows in some people during sleep but not in others. While being overweight or obese increases a person's risk of OSA, it is only one part of the problem. Some thin adults and children have OSA, and many overweight or obese people do not have OSA. In addition, many people with OSA struggle to benefit from current OSA treatments lik...
Gender
ALL
Eligibility criteria
- Inclusion Criteria for healthy airways participants:
- • Naturally ideal dental occlusion without orthodontic intervention, including successful eruption of wisdom teeth (without significant dental crowding, though minor rotation of less than 4 teeth will be acceptable)
- • No sleep-related complaints
- • No snoring.
- • They should be missing no more than 4 of their natural teeth, and these should have been lost to decay or accident rather than due to crowding. A person whose wisdom teeth came in successfully but were extracted "preventatively" will be eligible for the study.
- • Should be getting at least 6 hours of sleep nightly.
- • BMI between 18.5 and 35
- Inclusion Criteria for participants with OSA who are successful CPAP users:
- • Participant will have experienced significant benefits from therapy and have had such benefit since the first night of use. Participant should have no significant sleep complaints when using CPAP.
- • Uses CPAP \> 6 hours of nightly use on \> 90% of nights using a nasal mask.
- • Residual device AHI \< 5 events/hour.
- • Has used CPAP for at least 12 months.
- • Symptomatic at diagnosis, with polysomnography (PSG) showing AASM AHI 5-60 and symptoms attributable to OSA, with greater than 75% of the apneas and hypopneas being obstructive in nature. Home sleep apnea testing (HSAT) will also be accepted, with RDI 5-60, with greater than 75% of the apneas and hypopneas being obstructive in nature.
- • Should be getting at least 6 hours of sleep nightly.
- • BMI between 18.5 and 35
- Inclusion Criteria for participants with OSA who have CPAP intolerance:
- • Symptomatic, with polysomnography (PSG) showing AASM AHI 5-60 and symptoms attributable to OSA, with greater than 75% of the apneas and hypopneas being obstructive in nature. Home sleep apnea testing (HSAT) will also be accepted, with RDI 5-60, with greater than 75% of the apneas and hypopneas being obstructive in nature.
- • Attempted nightly use for at least 2 weeks (at least 12/14 nights), with average use \< 4 hours, and difficulty tolerating PAP during a titration study, with complaints of difficulty breathing with CPAP or other difficulties that are not clearly related to identifiable causes (claustrophobia, mask discomfort, untreated RLS, untreated mouth leak, poor sleep hygiene, drug use, etc.).
- • Must be able to breathe through their noses comfortably while awake.
- • Able and willing to do daily swallowing exercises (15-30 minutes per day) for a total of 14 weeks.
- • Able and willing to use a positional therapy device to avoid supine sleep and to adjust their CPAP device settings (instructions will be provided).
- • BMI between 18.5 and 35
- • Not actively undergoing bariatric treatment or planning to start bariatric treatment within the next 6 months.
- Exclusion Criteria for all participants:
- • Presence of symptomatic swallowing disorders, neuromuscular disorders affecting the upper airway, or neurodegenerative disorders.
- • Co-existing sleep disorders such as narcolepsy, untreated restless legs syndrome, circadian rhythm disorders, or behavioral insomnia/poor sleep hygiene.
- • Clinically significant congenital or acquired anomalies or history of surgery on the head and neck, excluding adenotonsillectomy, turbinate reduction, and septoplasty. Participants who had a tongue tie release outside of the newborn period will be excluded, but those who had tongue tie release in the newborn period will be eligible.
- • Known complex sleep apnea or a history of conditions that are associated with the development of complex sleep apnea, such as heart failure, atrial fibrillation, a history of stroke, or opioid use.
- • Prescription or nonprescription stimulant use (excluding caffeine).
- • Substance use disorder or nightly alcohol consumption, as these significantly interfere with normal sleep.
- • Current unstable illness (such as asthma, hypertension, cancer, etc.), kidney failure with restrictions on fluid consumption, or unplanned hospitalization in the past year for an ongoing condition.
- • Risk factors for harm from expiratory strength testing and training: history of spontaneous pneumothorax, presence of CSF drain, recent trauma involving head, neck, or chest, history of recurrent epistaxis, history of esophageal surgery, active or recent hemoptysis, history of lung transplant or lung resection, eardrum rupture or any other condition of the ear, uncontrolled gastroesophageal reflux, abdominal hernia or recent hernia repair, urinary or fecal incontinence, presence of aneurysm (such as cerebral or aortic).
- • Participants with CPAP intolerance only: Latex allergy in themselves or household members (due to balloon use in exercises).
- • Allergy to Micropore paper tape (used in home sleep testing and for participants with CPAP intolerance during 2-week CPAP trial and exercise intervention).
- • Pregnancy, actively trying to get pregnant, or sexually active and not using birth control (for people of child-bearing potential).
- • Has a condition that increases the risk of developing cancer, such as BRCA1/2.
- • Does not speak English fluently.
About Denise Dewald
Denise Dewald is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical development and regulatory compliance, she oversees a diverse portfolio of studies aimed at evaluating innovative therapies across various therapeutic areas. Denise is known for her collaborative approach, fostering partnerships with research institutions and healthcare professionals to ensure the successful execution of trials. Her focus on ethical practices and patient safety underpins her mission to contribute to the scientific community and enhance the quality of care available to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Denise Dewald, MD
Principal Investigator
MetroHealth Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported